206 related articles for article (PubMed ID: 16911495)
1. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation.
Filler G
Pediatr Transplant; 2006 Sep; 10(6):707-11. PubMed ID: 16911495
[TBL] [Abstract][Full Text] [Related]
2. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
[TBL] [Abstract][Full Text] [Related]
3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
4. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation.
Langers P; Press RR; Inderson A; Cremers SC; den Hartigh J; Baranski AG; van Hoek B
Ther Drug Monit; 2014 Apr; 36(2):141-7. PubMed ID: 24081208
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
Dipchand AI; Pietra B; McCrindle BW; Rosebrook-Bicknell HL; Boucek MM
J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
[TBL] [Abstract][Full Text] [Related]
7. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
Nashan B; Saliba F; Durand F; Barcéna R; Herrero JI; Mentha G; Neuhaus P; Bowles M; Patch D; Bernardos A; Klempnauer J; Bouw R; Ives J; Mamelok R; McKay D; Truman M; Marotta P
Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
[TBL] [Abstract][Full Text] [Related]
9. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
Grinyó JM; Ekberg H; Mamelok RD; Oppenheimer F; Sánchez-Plumed J; Gentil MA; Hernandez D; Kuypers DR; Brunet M
Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
[TBL] [Abstract][Full Text] [Related]
11. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation.
Filler G; Foster J; Berard R; Mai I; Lepage N
Transplant Proc; 2004 Jun; 36(5):1327-31. PubMed ID: 15251324
[TBL] [Abstract][Full Text] [Related]
12. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
Pape L; Ehrich JH; Offner G
Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
[TBL] [Abstract][Full Text] [Related]
14. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression.
Filler G; Zimmering M; Mai I
Pediatr Nephrol; 2000 Feb; 14(2):100-4. PubMed ID: 10684356
[TBL] [Abstract][Full Text] [Related]
16. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
Tredger JM; Brown NW; Adams J; Gonde CE; Dhawan A; Rela M; Heaton N
Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
[TBL] [Abstract][Full Text] [Related]
18. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Schmidt J; Budde K; Kuypers D; Le Meur Y; van der Werf M; Mamelok R; van Gelder T
Clin Pharmacol Ther; 2009 Sep; 86(3):319-27. PubMed ID: 19494809
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome.
Kaplan B
Curr Med Res Opin; 2006 Dec; 22(12):2355-64. PubMed ID: 17257450
[TBL] [Abstract][Full Text] [Related]
20. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]